Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Preferred Stock Liabilities: 2021

Historic Preferred Stock Liabilities for ARS Pharmaceuticals (SPRY) over the last 1 years, with Dec 2021 value amounting to $54.8 million.

  • ARS Pharmaceuticals' Preferred Stock Liabilities was N/A to $54.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $54.8 million, marking a year-over-year change of. This contributed to the annual value of $54.8 million for FY2021, which is N/A change from last year.
  • Per ARS Pharmaceuticals' latest filing, its Preferred Stock Liabilities stood at $54.8 million for FY2021.
  • ARS Pharmaceuticals' 5-year Preferred Stock Liabilities high stood at $54.8 million for FY2021, and its period low was $54.8 million during FY2021.
  • Moreover, its 1-year median value for Preferred Stock Liabilities was $54.8 million (2021), whereas its average is $54.8 million.